- The U.S. FDA has approved BRAVECTO® QUANTUM (fluralaner) for year-long flea and tick protection in dogs.
- BRAVECTO QUANTUM is the first injectable product offering 12-month coverage with a single dose.
- This product will be available at veterinary clinics across the U.S. by August 2025.
Merck Animal Health, a division of Merck & Co., Inc. (MRK, Financial), has received approval from the U.S. Food and Drug Administration (FDA) for BRAVECTO® QUANTUM. This new product is a once-yearly injectable suspension that offers extended-release protection against fleas and ticks for dogs.
BRAVECTO QUANTUM has already been approved in more than 50 countries, including Australia, New Zealand, and the European Union. The product is designed for dogs and puppies aged six months and older, providing 12 months of protection against several tick species, such as the black-legged tick, American dog tick, and brown dog tick. It also offers eight months of protection against the lone star tick.
The injectable formulation of BRAVECTO QUANTUM is particularly noteworthy for its ability to eliminate the need for monthly treatments, offering a more convenient option for both pet owners and veterinarians. Its unique fluralaner composition ensures effective levels are maintained for up to 12 months. Merck Animal Health aims to have this product available in veterinary clinics nationwide by August 2025.
Christine Royal, DVM, Vice President of Companion Animal and Equine Business Unit at Merck Animal Health, emphasized the capacity of BRAVECTO QUANTUM to set new standards in pet care, stating that it provides a safe and effective option for flea and tick protection for dogs. The product's year-long coverage simplifies care and promotes compliance among pet owners. This innovation underscores Merck's commitment to advancing veterinary science and improving animal health.
